Discussion
Dangerous blood clots that block blood flow are rare in people with von Willebrand disease (VWD), but their risk increases with age and the…
Regulatory authorities in Japan have approved Sanofi’s oral therapy Wayrilz (rilzabrutinib) for treating people with immune thrombocytopenia (ITP) who haven’t responded to, or cannot tolerate, other therapies. The marketing and manufacturing authorization from Japan’s Ministry of Health, Labor and Welfare follows similar approvals of Wayrilz in…
Latest news & perspectives
Discussion
Discussion
Four weekly injections of the antibody therapy daratumumab restored a key enzyme’s activity and triggered a two-year recovery for a woman with hard-to-treat immune-mediated…
